MAP makes second US FDA filing attempt for inhaled migraine product
This article was originally published in Scrip
Executive Summary
MAP Pharmaceuticals has re-filed for US FDA approval of its inhaled product Levadex for the acute treatment of migraine in adults, having, it says, addressed the issues raised in March’s Complete Response Letter.